Migraine headache without aura has at least 5 attacks of any 2 symptoms of unilateral headache that is throbbing or pulsating in nature, moderate to severe in pain and activity aggravates pain. It is accompanied with either nausea and vomiting or photophobia &/or phonophobia. The symptoms last for 4-72 hours without signs of secondary headache.
Migraine headache with aura has at least 2 attacks with any of the fully reversible symptoms of flickering lights, spots or lines &/or vision loss, sensory symptoms
of pins & needles &/or numbness and dysphasic speech disturbance but without motor weakness. Accompanied by at least 2 of the following symptoms of homonymous visual symptoms &/or unilateral sensory symptoms or at least 1 aura symptoms develop gradually over ≥5 minutes &/or different aura symptoms that occur in succession over ≥5 minutes.
Individuals who have failed between two and four preventive therapies for episodic migraine may derive benefit from a once-a-month dose of erenumab, according to results of the phase IIIb LIBERTY* study.
Migraine may potentially increase the risks of myocardial infarction, ischaemic stroke, haemorrhagic stroke, venous thromboembolism, and atrial fibrillation or atrial flutter, according to a recent study. In addition, migraine may be a significant predictor for most cardiovascular diseases.
Fully monoclonal antibodies that target the calcitonin gene–related peptide (CGRP), particularly fremanezumab and erenumab, show potential in migraine prevention, significantly reducing the frequency of attacks in patients with chronic or episodic migraine, according to data from two phase III trials.
Osteopathic manipulative therapy (OMT) demonstrates therapeutic potential in patients with high-frequency migraine and comorbid mood disorders, with the improvements observed after four 45-minute OMT sessions, a study has shown.
A history of migraine headache is a predictor of increased risk of future cardiovascular (CV) events (cardiovascular death, nonfatal myocardial infarction, heart failure or stroke) on long-term follow-up among women being evaluated for ischaemic heart disease, according to a study. Moreover, this risk is mainly driven by a more than twofold rise in stroke risk.
Clinicians often face the dilemma of overinvestigating headaches caused by benign ailments and overlooking headaches that are manifestations of serious underlying conditions, despite advances in diagnostic techniques.
Transcutaneous occipital nerve stimulation (tONS) shows promise in the prevention of migraine, with infrequent and mild adverse events, according to a study. The intervention may be effective among patients who favour nonpharmacological treatment.
Men were more likely to have better outcome than women among those who had been hospitalized for migraine or chronic tension type headache (CTTH), suggests a study presented at the Association of South-East Asian Pain Societies Congress 2017 (ASEAPS 2017) held in Yangon, Myanmar.
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
New drug applications approved by US FDA as of 1 - 15 June 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Drinking more water did not significantly slow down the decline in kidney function of patients with stage 3 chronic kidney disease (CKD) at 1 year compared with patients who maintained their daily water intake, the CKD WIT* randomized study suggests.